Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients
NCT07491042Recruiting
- Sponsor
- Oman Ministry of Health
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dapagliflozin in end-stage kidney disease (ESKD), sponsored by Oman Ministry of Health. Primary endpoints: Change in ultrafiltration volume at 3 months, Change in Kt/V (dialysis adequacy) at 6 months and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NCT07491042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491042.